Back to Search
Start Over
Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma
- Source :
- International Journal of Molecular Sciences, 14, 11402-23, International Journal of Molecular Sciences, 14, 6, pp. 11402-23, International Journal of Molecular Sciences, International Journal of Molecular Sciences, Vol 14, Iss 6, Pp 11402-11423 (2013)
- Publication Year :
- 2013
-
Abstract
- Contains fulltext : 117856.pdf (Publisher’s version ) (Open Access) Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase IX (CAIX). CAIX is expressed by virtually all renal cell carcinomas of the clear cell type (ccRCC), but expression in normal tissues is restricted. The homogeneous CAIX expression in ccRCC and excellent targeting capability of mAbG250 in animal models led to the initiation of the clinical evaluation of mAbG250 in (metastatic) RCC (mRCC) patients. Clinical studies confirmed the outstanding targeting ability of mAbG250 and cG250 PET imaging, as diagnostic modality holds great promise for the future, both in detecting localized and advanced disease. Confirmation of the results obtained in the non-randomized clinical trials with unmodified cG250 is needed to substantiate the value of cG250 treatment in mRCC. cG250-Based radio immuno-therapy (RIT) holds promise for treatment of patients with small-volume disease, and adjuvant treatment with unmodified cG250 may be of value in selected cases. In the upcoming years, ongoing clinical trials should provide evidence for these assumptions. Lastly, whether cG250-based RIT can be combined with tyrosine kinase inhibitors, which constitutes the current standard treatment for mRCC, needs to be established.
- Subjects :
- Pathology
medicine.medical_treatment
Review
Aetiology, screening and detection [ONCOL 5]
clear cell renal cell carcinoma
lcsh:Chemistry
Monoclonal antibody G250
Renal cell carcinoma
G250
lcsh:QH301-705.5
Spectroscopy
Carbonic Anhydrases
Clinical Trials as Topic
Standard treatment
Translational research Immune Regulation [ONCOL 3]
Antibodies, Monoclonal
imaging
General Medicine
RCC
Translational research Tissue engineering and pathology [ONCOL 3]
Kidney Neoplasms
Computer Science Applications
Radioimmunotherapy
medicine.drug
medicine.medical_specialty
medicine.drug_class
Monoclonal antibody
Catalysis
Inorganic Chemistry
Antigens, Neoplasm
Translational research [ONCOL 3]
medicine
Carcinoma
Animals
Humans
girentuximab
Physical and Theoretical Chemistry
Carcinoma, Renal Cell
Molecular Biology
business.industry
Girentuximab
Organic Chemistry
CAIX
medicine.disease
Clear cell renal cell carcinoma
lcsh:Biology (General)
lcsh:QD1-999
monoclonal antibody
radioimmunotherapy
Cancer research
business
Subjects
Details
- ISSN :
- 14220067
- Database :
- OpenAIRE
- Journal :
- International Journal of Molecular Sciences, 14, 11402-23, International Journal of Molecular Sciences, 14, 6, pp. 11402-23, International Journal of Molecular Sciences, International Journal of Molecular Sciences, Vol 14, Iss 6, Pp 11402-11423 (2013)
- Accession number :
- edsair.doi.dedup.....acd6377fe2b94d535ac1a118c34313d5